CALL/ROCHE GS/400/0.1/20.09.24 Share Price

Warrant

DE000GQ54C23

Real-time BOERSE MUENCHEN 09:55:33 24/06/2024 pm IST
0.012 EUR -25.00% Intraday chart for CALL/ROCHE GS/400/0.1/20.09.24
Current month+100.00%
1 month+100.00%
Date Price Change
24/24/24 0.012 -25.00%
21/24/21 0.016 +14.29%
20/24/20 0.014 -17.65%
19/24/19 0.017 +30.77%
18/24/18 0.013 0.00%

Real-time BOERSE MUENCHEN

Last update June 24, 2024 at 09:55 pm IST

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer Goldman Sachs
WKN GQ54C2
ISINDE000GQ54C23
Date issued 19/09/2023
Strike 400 CHF
Maturity 20/09/2024 (88 Days)
Parity 10 : 1
Emission price 0.09
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.094
Lowest since issue 0.004
Spread 0.15
Spread %93.75%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
255.4 CHF
Average target price
278.1 CHF
Spread / Average Target
+8.87%
Consensus